Expres2ion Biotech

Upcoming events

• 19/05/21

  Interim report, Q1 2021

• 26/05/21

  Annual General Meeting, 2021

• 19/08/21

  Half-year report, 2021

• 18/11/21

  Interim report, Q3 2021

• 24/02/22

  Year-end report, 2022

Latest press releases

Interim safety update on COUGH-1, the COVID-19 clinical phase I/II study for the ABNCoV2 vaccine

12-04-2021 Regulatory pressrelease

Hørsholm, Denmark, April 12, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that the first group of volunteers in the clinical Phase I/II study, COUGH-1, have been satisfactorily administered with the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 vaccine. The clinical study runs as planned with no untoward safety signal in…

Read more

ExpreS2ion announces T04 warrant exercise price, start of subscription period and Board and Executive Management commitment to fully exercise their T04 warrant holdings

12-04-2021 Regulatory pressrelease

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. Hørsholm,…

Read more

View all